Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) can potentially reduce how well oral contraceptive pills are absorbed, particularly during the early weeks of treatment when the medicine is slowing digestion most noticeably. This is a genuine clinical consideration, not a theoretical one — your prescriber needs to know you take oral contraception before starting. Wegovy is a prescription-only medicine, so a clinician assesses your full picture before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works partly by slowing how quickly food and other substances leave the stomach, a process called delayed gastric emptying. That's useful for appetite control, but it also means oral medicines can sit in the stomach longer before being absorbed into the bloodstream. For most tablets this matters little. For the contraceptive pill, which depends on consistent and predictable absorption to maintain its protective effect, the picture is less clear-cut.
The concern isn't that semaglutide chemically interferes with the pill's hormones. It's that slower gut transit may reduce or delay how much of the pill's active ingredient reaches your bloodstream. If you want a thorough grounding in how Wegovy can affect the pill and what that means for your contraceptive cover, we cover the question in full detail on a dedicated page. You can read the NHS England guidance on weight-management injections, which addresses this directly, on the NHS England medicines for obesity page.
The effect is also likely dose-dependent. At 0.25mg (the starting dose) gastric slowing is modest; as doses increase through the titration schedule, the effect tends to intensify. That trajectory matters when you're thinking about your contraceptive risk window.
NHS guidance recommends that women using oral contraceptives discuss their contraception with a clinician before starting Wegovy. The practical suggestion is to consider switching to a non-oral method, such as a contraceptive patch, implant, injection or coil, for the duration of treatment. These routes bypass the gut entirely, so gastric emptying is irrelevant to how reliably they work.
If switching isn't possible or desirable, adding a barrier method (condoms) during the escalation phase is a reasonable interim step, discussed with your prescriber. The NHS semaglutide medicines page includes guidance on what to tell your doctor before starting.
One distinction worth knowing: for the Wegovy tablet (oral semaglutide, approved by the MHRA in June 2026), the interaction question takes a slightly different shape, since the medicine itself is taken orally and the timing rules around it (empty stomach, no other medicines for 30 minutes) already affect how you'd take an oral contraceptive on the same morning. That's a separate conversation, covered in more detail on our Wegovy and the pill page.
The tirzepatide comparison is also worth a brief mention. For Mounjaro (tirzepatide), NHS guidance is more specific: oral contraceptive users should add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase. There is no equivalent explicit instruction for semaglutide, but the underlying mechanism (gastric slowing) is shared, which is why the general caution still applies.
The absorption question shouldn't put you off treatment. It's a manageable consideration, not a barrier. The decision tree is relatively straightforward: tell your prescriber you take the pill, discuss which contraceptive switch or addition suits you, and proceed with that plan in place. Most women find a workable solution quickly, many had already been thinking about a longer-acting contraceptive method anyway.
Worth doing before your consultation: check the name of your contraceptive pill and whether it's combined (oestrogen and progestogen) or progestogen-only. That information takes about 30 seconds to find on the packet and gives your prescriber something concrete to work with immediately.
For context on what the treatment itself involves, including eligibility and how the dose schedule works, the Wegovy treatment overview is a good starting point. Our weight-loss treatment page also covers the full range of licensed options if you're still deciding. If you'd like to see how the clinical team approaches these questions, our clinical lead's profile gives you a sense of the oversight behind every prescription.
A consultation is the right place to work through the specifics. Bring the name of your current pill, how long you've been taking it, and any other medicines you take regularly. Your prescriber will review everything before any prescription is issued, that review is where the contraception conversation happens, not as an afterthought.
If Wegovy sounds right for you and you'd like to understand the cost alongside the clinical picture, the Wegovy pill pricing page sets out what private treatment involves. For background on how and when the Wegovy tablet received UK approval, the approval history page has the detail. Further general FAQs are on the faqs page.
Once you're ready, checking your eligibility takes a few minutes and puts your case in front of a GPhC-registered prescriber the same day, a real clinician, reading your answers, not a form-sorting algorithm.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.